Periprocedural heparin bridging in patients receiving vitamin K antagonists: Systematic review and meta-analysis of bleeding and thromboembolic rates

Circulation

Volumn 126, Issue 13, 2012, Pages 1630-1639

  Siegal, Deborah ^a   Yudin, Jovana ^a   Kaatz, Scott ^b   Douketis, James D ^a   Lim, Wendy ^a   Spyropoulos, Alex C ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b HENRY FORD HOSPITAL   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

anticoagulants; bridging; heparin; periprocedural; thromboembolism; warfarin

Indexed keywords

ANTIVITAMIN K; ARDEPARIN; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

ANTICOAGULANT THERAPY; ARTERIAL THROMBOEMBOLISM; BLEEDING; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; PERIPROCEDURAL BRIDGING ANTICOAGULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMORRHAGE; HEPARIN; HUMANS; MIDDLE AGED; PERIOPERATIVE CARE; PREVALENCE; RISK FACTORS; SURGICAL PROCEDURES, ELECTIVE; THROMBOEMBOLISM; VITAMIN K; YOUNG ADULT;

EID: 84866698766     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.105221     Document Type: Review

References (50)

1. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R. Perioperative management of antithrombotic therapy: Antithrombotic therapy and prevention of thrombosis, 9th edi-tion: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e326S-e350S.
2. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336:1506-1511.
3. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: A systematic review. Arch Intern Med. 2003;163: 901-908. (Pubitemid 36522737)
4. Spyropoulos AC. Bridging therapy and oral anticoagulation: Current and future prospects. Curr Opin Hematol. 2010;17:444-449.
5. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: A proposal for reporting: Meta-Analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283:2008-2012. (Pubitemid 30214957)
6. McGinn T, Wyer PC, Newman TB, Keitz S, Leipzig R, Guyatt G; Evidence-Based Medicine Teaching Tips Work Group. Tips for learners of evidence-based medicine, 3: Measures of observer variability (kappa statistic). CMAJ. 2004;171:1369-1373. (Pubitemid 39573841)
7. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
8. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care. 1990;6:5-30. (Pubitemid 20287159)
9. Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, Young G, Bidlingmaier C, Brandao LR, Ettingshausen CE, Gringeri A, Kenet G, Knofler R, Kreuz W, Kurnik K, Manner D, Santagostino E, Mannucci PM, Nowak-Gottl U. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: A systematic review. J Thromb Haemost. 2010;8:1256-1265.
10. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560. (Pubitemid 37088507)
11. Bajkin BV, Popovic SL, Selakovic SDJ. Randomized, prospective trial comparing bridging therapy using low-molecular-weight heparin with maintenance of oral anticoagulation during extraction of teeth. J Oral Maxillofac Surg. 2009;67:990-995.
12. Bombuy E, Mans E, Hugue A, Plensa E, Rodriguez L, Prats M, Sunol X. Elective inguinal hernioplasty in patients on chronic anticoagulation therapy: Management and outcome. Cir Esp. 2009;86:38-42.
13. Bui HT, Krisnaswami A, Le C-U, Chan J, Shenoy B-N. Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation. Am J Cardiol. 2009;104:1429-1433.
14. Cheng M, Hua W, Chen K, Pu J, Ren X, Zhao X, Liu Z, Wang F, Chen X, Zhang S. Perioperative anticoagulation for patients with mechanic heart valve(s) undertaking pacemaker implantation. Europace. 2009;11: 1183-1187.
15. Constans M, Santamaria A, Mateo J, Pujol N, Souto JC, Fontcuberta J. Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy. Int J Clin Pract. 2007;61:212-217.
16. Daniels PR, McBane RD, Litin SC, Ward SA, Hodge DO, Dowling NF, Heit JA. Peri-procedural anticoagulation management of mechanical prosthetic heart valve patients. Thromb Res. 2009;124:300-305.
17. Dotan ZA, Mor Y, Leibovitch I, Varon D, Golomb J, Duvdevani M, Ramon J. The efficacy and safety of perioperative low molecular weight heparin substitution in patients on chronic oral anticoagulant therapy undergoing transurethral prostatectomy for bladder outlet obstruction. J Urol. 2002;168:610-613, discussion 614.
18. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: Assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004;164:1319-1326. (Pubitemid 38828883)
19. Douketis JD, Woods K, Foster GA, Crowther MA. Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost. 2005;94:528-531. (Pubitemid 41300847)
20. Dunn AS, Spyropoulos AC, Turpie AGG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: The Prospective Perioperative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost. 2007;5:2211-2218. (Pubitemid 47617873)
21. Ercan M, Bostanci EB, Ozer I, Ulas M, Ozogul YB, Teke Z, Akoglu M. Postoperative hemorrhagic complications after elective laparoscopic cholecystectomy in patients receiving long-term anticoagulant therapy. Langenbecks Arch Surg. 2010;395:247-253.
22. Garcia DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, Hylek EM. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008;168:63-69.
23. Ghanbari H, Feldman D, Schmidt M, Ottino J, Machado C, Akoum N, Wall TS, Daccarett M. Cardiac resynchronization therapy device implantation in patients with therapeutic international normalized ratios. Pacing Clin Electrophysiol. 2010;33:400-406.
24. Halbritter KM, Wawer A, Beyer J, Oettler W, Schellong SM. Bridging anticoagulation for patients on long-term vitamin-K-antagonists: A prospective 1 year registry of 311 episodes. J Thromb Haemost. 2005;3: 2823-2825. (Pubitemid 41819819)
25. Jaffer AK, Ahmed M, Brotman DJ, Bragg L, Seshadri N, Qadeer MA, Klein A. Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: A standardized bridging therapy protocol. J Thromb Thrombolysis. 2005;20:11-16. (Pubitemid 41300615)
26. Jaffer AK, Brotman DJ, Bash LD, Mahmood SK, Lott B, White RH. Variations in perioperative warfarin management: Outcomes and practice patterns at nine hospitals. Am J Med. 2010;123:141-150.
27. Kovacs MJ, Kearon C, Rodger M, Anderson DR, Turpie AGG, Bates SM, Desjardins L, Douketis J, Kahn SR, Solymoss S, Wells PS. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation. 2004;110:1658-1663. (Pubitemid 39297990)
28. Malato A, Saccullo G, Lo Coco L, Caramazza D, Abbene I, Pizzo G, Casuccio A, Siragusa S. Patients requiring interruption of long-term oral anticoagulant therapy: The use of fixed sub-therapeutic doses of lowmolecular-weight heparin. J Thromb Haemost. 2010;8:107-113.
29. Marquie C, De Geeter G, Klug D, Kouakam C, Brigadeau F, Jabourek O, Trillot N, Lacroix D, Kacet S. Post-operative use of heparin increases morbidity of pacemaker implantation. Europace. 2006;8:283-287. (Pubitemid 43905736)
30. McBane RD, Wysokinski WE, Daniels PR, Litin SC, Slusser J, Hodge DO, Dowling NF, Heit JA. Periprocedural anticoagulation management of patients with venous thromboembolism. Arterioscler Thromb Vasc Biol. 2010;30:442-448.
31. O'Donnell MJ, Kearon C, Johnson J, Robinson M, Zondag M, Turpie I, Turpie AG. Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin [summary for patients in Ann Intern Med. 2007;146:I35]. Ann Intern Med. 2007;146:184-187. (Pubitemid 351650631)
32. Pengo V, Cucchini U, Denas G, Erba N, Guazzaloca G, La Rosa L, De Micheli V, Testa S, Frontoni R, Prisco D, Nante G, Iliceto S; Italian Federation of Centers for the Diagnosis of Thrombosis and Management of Antithrombotic Therapies (FCSA). Standardized low-molecularweight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: An inception cohort management study. Circulation. 2009;119:2920-2927.
33. Robinson M, Healey JS, Eikelboom J, Schulman S, Morillo CA, Nair GM, Baranchuk A, Ribas S, Evans G, Connolly SJ, Turpie AG. Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators. Pacing Clin Electrophysiol. 2009;32:378-382.
34. Spyropoulos AC, Jenkins P, Bornikova L. A disease management protocol for outpatient perioperative bridge therapy with enoxaparin in patients requiring temporary interruption of long-term oral anticoagulation. Pharmacotherapy. 2004;24:649-658. (Pubitemid 38585959)
35. Spyropoulos AC, Frost FJ, Hurley JS, Roberts M. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest. 2004;125:1642-1650. (Pubitemid 38648392)
36. Spyropoulos AC, Turpie AGG, Dunn AS, Spandorfer J, Douketis J, Jacobson A, Frost FJ; REGIMEN Investigators. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: The REGIMEN registry. J Thromb Haemost. 2006;4:1246-1252.
37. Spyropoulos AC, Turpie AGG, Dunn AS, Kaatz S, Douketis J, Jacobson A, Petersen H, Investigators R. Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). Am J Cardiol. 2008;102:883-889.
38. Tinmouth AH, Morrow BH, Cruickshank MK, Moore PM, Kovacs MJ. Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis. Ann Pharmacother. 2001;35:669-674. (Pubitemid 32523598)
39. Tischenko A, Gula LJ, Yee R, Klein GJ, Skanes AC, Krahn AD. Implantation of cardiac rhythm devices without interruption of oral anticoagu-lation compared with perioperative bridging with low-molecular weight heparin. Am Heart J. 2009;158:252-256.
40. Tompkins C, Cheng A, Dalal D, Brinker JA, Leng CT, Marine JE, Nazarian S, Spragg DD, Sinha S, Halperin H, Tomaselli GF, Berger RD, Calkins H, Henrikson CA. Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol. 2010;55:2376-2382.
41. Varkarakis IM, Rais-Bahrami S, Allaf ME, Lima GC, Permpongkosol S, Rao P, Jarrett TW, Kavoussi LR. Laparoscopic renal-adrenal surgery in patients on oral anticoagulant therapy. J Urol. 2005;174:1020-1023. (Pubitemid 41140667)
42. Wazni OM, Beheiry S, Fahmy T, Barrett C, Hao S, Patel D, Di Biase L, Martin DO, Kanj M, Arruda M, Cummings J, Schweikert R, Saliba W, Natale A. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: Comparison of strategies of anticoagulation management in the periprocedural period. Circulation. 2007;116:2531-2534. (Pubitemid 350179218)
43. Wilson SJ, Morgan J, Gray L, Newman V, Anderson DR. A model for perioperative outpatient management of anticoagulation in high-risk patients: An evaluation of effectiveness and safety. Can J Hosp Pharm. 2001;54:269-277. (Pubitemid 33094821)
44. Wysokinski WE, McBane RD, Daniels PR, Litin SC, Hodge DO, Dowling NF, Heit JA. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation [erratum appears in Mayo Clin Proc. 2008;83:851]. Mayo Clin Proc. 2008;83:639-645. (Pubitemid 351810563)
45. Connolly SJ, Eikelboom JW, Ng J, Hirsh J, Yusuf S, Pogue J, de Caterina R, Hohnloser S, Hart RG. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med. 2011;155:579-586.
46. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-1127.
47. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M. Peri-procedural bleeding and thromboembolic events with dabigatran compared to warfarin: Results from the RE-LY randomized trial. Circulation. 2012;126:343-348.
48. Spyropoulos AC, Douketis J, Gerotziafas G, Kaatz S, Ortel T, Schulman S. Periprocedural antithrombotic and bridging therapy: Recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. J Thromb Haemost. 2012;10:692-694.
49. Ortel TL, Hasselblad V. Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study). www.ClinicalTrials.gov. Identifier: NCT00786474. Accessed July 17, 2012.
50. Kovacs MJ. PERIOP 2: A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin. www.ClinicalTrials.gov. Identifier: NCT00432796. Accessed July 17, 2012.